Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    ATH434

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alterity Pharma Gets Favorable FDA Input After ATH434 Phase 3
    Alterity Pharma Gets Favorable FDA Input After ATH434 Phase 3

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264513/0/en/Alterity-Therapeutics-Receives-Positive-FDA-Feedback-Following-Type-C-Meeting-on-ATH434-Phase-3-Program.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Alterity Therapeutics Releases Q2 FY26 Cash Flow Report & Updates
    Alterity Therapeutics Releases Q2 FY26 Cash Flow Report & Updates

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229461/0/en/Alterity-Therapeutics-Appendix-4C-Q2-FY26-Quarterly-Cash-Flow-Report-Corporate-Update.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share
    Alterity Issues Shareholder Letter Highlighting 2025 Progress
    Alterity Issues Shareholder Letter Highlighting 2025 Progress

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222672/0/en/Alterity-Therapeutics-Issues-Shareholder-Letter-Highlighting-2025-Progress-and-Key-Objectives-for-2026.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    Alterity Therapeutics Showcases Ath434's Positive Effect On MSA
    Alterity Therapeutics Showcases Ath434's Positive Effect On MSA

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184418/0/en/Alterity-Therapeutics-Presents-Promising-Impact-of-ATH434-on-Orthostatic-Hypotension-and-Disease-Progression-in-MSA-at-the-36th-International-Symposium-on-the-Autonomic-Nervous-Sys.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    Alterity Therapeutics Releases Q1 FY26 Cash Flow Report
    Alterity Therapeutics Releases Q1 FY26 Cash Flow Report

    31 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/31/3178235/0/en/Alterity-Therapeutics-Appendix-4C-Q1-FY26-Quarterly-Cash-Flow-Report.html

    GLOBENEWSWIRE
    31 Oct 2025
    Share Share
    Alterity Reveals Positive ATH434 Ph 2 Trial Results At Congress
    Alterity Reveals Positive ATH434 Ph 2 Trial Results At Congress

    09 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/09/3164032/0/en/Alterity-Therapeutics-Presents-Positive-Data-from-ATH434-Phase-2-Trial-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html

    GLOBENEWSWIRE
    09 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.